Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa L Johnson

Showing results (21-30 of 94) with videos related to

Pageof 10
Sort By:
JAMA Oncology|May 31, 2019
Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation TrialMelissa L Johnson, Fadi Braiteh, Juneko E Grilley-Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2015
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsMelissa L Johnson, Helena A Yu, Eric M Hart, et al.
Targeted Oncology|February 16, 2020
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung CancerTodd M Bauer, Alice T Shaw, Melissa L Johnson, et al.
Gynecologic Oncology Reports|October 2, 2015
FGFR3-TACC3: A novel gene fusion in cervical cancerBenedito A Carneiro, Julia A Elvin, Suneel D Kamath, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 31, 2011
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinibMelissa L Johnson, Greg J Riely, Naiyer A Rizvi, et al.
Future Oncology (London, England)|August 11, 2022
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive non-small-cell lung cancerMasahiro Tsuboi, Jonathan W Goldman, Yi-Long Wu, et al.
Cancer|May 19, 2012
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomasPaul K Paik, Melissa L Johnson, Sandra P D'Angelo, et al.
Clinical Lung Cancer|February 27, 2026
TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung CancerLuis G Paz-Ares, Kenneth John O'Byrne, Melissa L Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomasSandra P D'Angelo, M Catherine Pietanza, Melissa L Johnson, et al.
Journal of Hematology & Oncology|June 24, 2023
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancerCharles M Rudin, Martin Reck, Melissa L Johnson, et al.
Pageof 10

Showing results (21-30 of 94) with videos related to

Sort By:
Pageof 10
JAMA Oncology|May 31, 2019
Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation TrialMelissa L Johnson, Fadi Braiteh, Juneko E Grilley-Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2015
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsMelissa L Johnson, Helena A Yu, Eric M Hart, et al.
Targeted Oncology|February 16, 2020
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung CancerTodd M Bauer, Alice T Shaw, Melissa L Johnson, et al.
Gynecologic Oncology Reports|October 2, 2015
FGFR3-TACC3: A novel gene fusion in cervical cancerBenedito A Carneiro, Julia A Elvin, Suneel D Kamath, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 31, 2011
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinibMelissa L Johnson, Greg J Riely, Naiyer A Rizvi, et al.
Future Oncology (London, England)|August 11, 2022
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive non-small-cell lung cancerMasahiro Tsuboi, Jonathan W Goldman, Yi-Long Wu, et al.
Cancer|May 19, 2012
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomasPaul K Paik, Melissa L Johnson, Sandra P D'Angelo, et al.
Clinical Lung Cancer|February 27, 2026
TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung CancerLuis G Paz-Ares, Kenneth John O'Byrne, Melissa L Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomasSandra P D'Angelo, M Catherine Pietanza, Melissa L Johnson, et al.
Journal of Hematology & Oncology|June 24, 2023
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancerCharles M Rudin, Martin Reck, Melissa L Johnson, et al.
Pageof 10